Vor Biopharma Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Vor Biopharma Inc. (VOR) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$216.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$216.00K.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$747.00K, a 74800.00% decline year-over-year.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $29.00K.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$2.00K, a 101.45% decline year-over-year.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $19.00K, a 80.81% decline from fiscal 2024.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $99.00K, a 85.71% decline from fiscal 2023.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $693.00K.
- Vor Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$770.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$216.00K 10-Q · filed 2026-08-11 | -$963.00K 10-Q · filed 2026-08-11 | -$934.00K derived: sum of 3 quarters · filed 2026-08-11 | -$936.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$747.00K 10-Q · filed 2026-08-11 | -$718.00K derived: sum of 2 quarters · filed 2026-08-11 | -$720.00K derived: sum of 3 quarters · filed 2026-08-11 | -$729.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $27.00K derived: sum of 2 quarters · filed 2026-03-30 | $18.00K derived: sum of 3 quarters · filed 2026-08-11 | $19.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.00K 10-Q · filed 2025-11-13 | -$11.00K derived: sum of 2 quarters · filed 2026-08-11 | -$10.00K 10-Q · filed 2025-11-13 | -$56.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$9.00K 10-Q · filed 2026-08-11 | -$8.00K 10-Q · filed 2026-08-11 | -$54.00K derived: sum of 3 quarters · filed 2026-08-11 | $84.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-08-11 | -$45.00K derived: sum of 2 quarters · filed 2026-08-11 | $93.00K derived: sum of 3 quarters · filed 2026-08-11 | $110.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $92.00K derived: sum of 2 quarters · filed 2026-03-30 | $109.00K derived: sum of 3 quarters · filed 2026-03-30 | $99.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $138.00K 10-Q · filed 2025-11-13 | $155.00K derived: sum of 2 quarters · filed 2025-11-13 | $145.00K 10-Q · filed 2025-11-13 | $348.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $17.00K 10-Q · filed 2025-11-13 | $7.00K 10-Q · filed 2025-08-12 | $210.00K derived: sum of 3 quarters · filed 2025-11-13 | $366.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$10.00K 10-Q · filed 2025-11-13 | $193.00K derived: sum of 2 quarters · filed 2025-11-13 | $349.00K derived: sum of 3 quarters · filed 2025-11-13 | $87.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $359.00K derived: sum of 2 quarters · filed 2025-03-20 | $97.00K derived: sum of 3 quarters · filed 2025-03-20 | $693.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $156.00K 10-Q · filed 2024-11-07 | -$106.00K derived: sum of 2 quarters · filed 2024-11-07 | $490.00K 10-Q · filed 2024-11-07 | $898.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$262.00K 10-Q · filed 2024-11-07 | $334.00K 10-Q · filed 2024-08-08 | $742.00K derived: sum of 3 quarters · filed 2024-11-07 | $890.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $596.00K 10-Q · filed 2024-11-07 | $1.00M derived: sum of 2 quarters · filed 2024-11-07 | $1.15M derived: sum of 3 quarters · filed 2024-11-07 | $898.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $556.00K derived: sum of 2 quarters · filed 2024-03-20 | $302.00K derived: sum of 3 quarters · filed 2024-03-20 | -$770.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $148.00K 10-Q · filed 2023-11-07 | -$106.00K derived: sum of 2 quarters · filed 2023-11-07 | -$1.18M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$254.00K 10-Q · filed 2023-11-07 | -$1.33M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$1.07M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |